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Letters to the Editor
Sir,
We read with interest the article by Coleman et al reportinc on
prognostic factors at the time of diagnosis of metastatic breast
cancer. The factors which the investigators found are precisely
those which we reported previously (Williams et al. 1986:
Robertson et al. 1992). We are surprised that the authors appear
unaware of this previous work as it has been widely presented in
addition to being published. Blanco and colleagues also reported
similar findings in this very journal in 1991 (Blanco et al. 1991).
The investigators in this case did not use Cox analysis. from
which the 3-values generated mav be used to construct an index
which prospectively places patients in different prognostic groups.
Only bv doing so can the work have any clinical application.
Blanco found that the index which we had derived (Wlliams et al.
1986) and confirmed (Robertson et al. 1992) worked very well in
his population (Blanco et al. personal communication). Having
identified independent factors. wve wonder what is the value ofthis
ifone does not combine them into a clinicallv useful index.
JFR Robertson and RWBlamey; City Hospital. Hucknall Road.
Nottingham NG5 IPB. UK
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Reply to the letter from Robertson to Blamey
Sir,
We are well aware of the prognostic factors in advanced breast
cancer described by the Nottingham Group and many other centres
around the world. but Robertson and Blamey appear to have
missed the point of our publication. Our series relates specifically
to breast cancer patients with bone as the first site of recurrence
and contains 4-5 times the number of patients with this problem
compared with the references cited by them. Our study investi-
gates factors which may determine the subsequent clinical course
of this specific subgroup and evaluates factors which predict for
disease remaining confined to the skeleton. The aim of the study
was to define patient groups who are mostly likely to develop
skeleton-related events as their dominant clinical problem and.
thus. benefit most from bisphosphonate treatment.
We did use the Cox regression anal sis. but chose not to
construct a prognostic index because the next stage of investiga-
tion is to correlate the exact number of skeleton-related events
with the prognostic subgroups we have defined to determine
whether these are indeed a greater clinical problem in those
patients with bone-only disease and a prolonged survival. Only
then can rational guidelines be made on the selection of patients
for bisphosphonate treatment.
RE Coleman andRDRubens. Department ofClinical Oncology;
The University ofSheffield, Weston Park- Hospital NHS Trust,
Whitham Road, Sheffield S1O 2SJ. UK
Ultraviolet radiation and cutaneous lymphoma
Sir,
Iscovich et al (1998) point to the immunosuppressive effect of
ultraviolet radiation (UV) as a possible factor in the development
of cutaneous lymphoma. However. they overlook the direct anti-
neoplastic effect of UV-B on early stage cutaneous T-cell
lymphoma (CTCL). The effectiveness ofUV-B in the treatment of
early stage CTCL. especially patch-stage mycosis fungoides (MF).
is well documented (Hermann et al. 1995). The sun-protected
regions. for example the bathing-trunk area and the female breasts.
are sites ofpredilection for lesions ofMF. By contrast. the face and
dorsa ofthe hands are relativeely uncommon locations.
The authors use the term cutaneous lymphoma (CL) to include
both MF and non-MF cutaneous lymphomas. They then compare
the incidence of CL in Israel with that reported by Weinstock
and Horm (1988) for the USA. However. the data of Weinstock
and Horm refer specifically only to MF [including the Sezary
svndrome (SS)]. In the registry for CL of the European
Organization for Research and Treatment of Cancer (EORTC)
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Cutaneous Lymphoma Project Group (Burg et al. 1998) involv-
inc 827 patients CTCL. which includes MF and SS. was four
times as frequent as cutaneous B-cell (CBCL) Ixmphoma. This
indicates that in the EORTC data non-MF CL comprises about
20% of all CLs. Over 700 patients with CL have been registered
at the University of California. San Francisco CL. USA. clinic
since 1971. Approximately 5-6%- were of the non-MF type
(unpublished data). Therefore. the comparison of Iscovich et al's
(1998) data with that of Weinstock and Horm (1988) requires
qualification.
The authors note that the incidence ofCL in the USA rose from
1973 to 1984. ... and may have continued to rise (Weinstock.
1994: Koh et al. 1995). However. I could find no data or state-
ment in either of those two articles to support the suggestion of a
continued increase in the incidence ofCL since 1984. In fact. Koh
et al (1995) state. However. preliminary analyses did not find
that the crude incidence of MF continued to increase during the
subsequent 6 years (MA Weinstock. unpublished data).
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Possible relationship of the apolipoprotein E (ApoE) £4
allele to prostate cancer
Sir,
Mantzoros et al ( 1997) report that increased insulin-like growth
factor I levels are a risk factor for prostate cancer. Another molec-
ular marker. the apolipoprotein E (ApoE) E4 allele. is a risk factor
for Alzheimer's disease (Poirier et al. 1993) and might be a risk
factor for prostate cancer as well.
Alzheimer's disease and prostate cancer share a common inci-
dence pattern. Onset ofAlzheimer's disease before age 60 is infre-
quent and caused by specific gene abnormalities. Prostate cancer is
also rare in men before age 60. and there is generallv a stronc
genetic component in these cases. As men get older. the prostate
cancer incidence continues to increase. and the older cases do
not generally have a family histor- (Stephenson. 1996). Like
Alzheimer's disease. the supposition is that if men get old enough
most will develop prostate cancer.
Among the three ApoE alleles. the E4 allele confers the hirhest
Alzheimer's disease risk. The £3 allele is associated with less risk.
and the c2 allele appears to be protective. The E--E-4 genotype (i.e.
two E4 alleles) confers the highest risk of all (Strittmatter and
Roses. 1995).
The antioxidant activity ofApoE alleles protects cells in culture
from oxidative damage. The E2 allele is most protective. the E3
allele less so. and the E4 allele least protective of all (Miyata and
Smith. 1996). The decreased antioxidant activity- of E4 could
contribute to its association with Alzheimer's disease. Because
antioxidants also protect against cancer(Duthieetal. 1996).theC4
allele might predispose to the development ofmaligrnant disease.
In 35 men with prostate cancer. ApoE grenotvpe wvas determined
by polv-merase chain reaction with a standard method (Slooter et
al. 1997). The frequency of the E4 allele was 0.24. This may be
compared with a control c4 allele frequency of 0.135 or 0.138.
reported by Slooter et al (1997). The increased frequency ofthe c4
allele in the prostate cancer cases resembles its increased
frequencv in dementia of0.22 (Slooter et al. 1997).
Furthermore. the t-o prostate cancer patients who were
homozvgous £4--4 were age 52 and 58 vears. significantly
younger than the average age (67 ± 5.7 -ears. mean ± s.d.) of
the 33 other patients (P = 0.0248. Maann-Whitney U' test and
Wilcoxon rank sum It'-test corrected for ties). In Alzheimer's
disease. the patients who are homozygous £4--E4 also have the
earliest disease onset (Blacker et al. 1997). Thus. further investiga-
tion of the possible relationship of ApoE to prostate cancer. and
perhaps other forms ofcancer. might be worthwhile.
S Lehrer, 30 West 60th Street. New York-,NY 100)3. USA
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